M

MiMedx Group

MDXG

6.68000
USD
-0.79
(-10.58%)
مفتوح الان
حجم التداول
5,161
الربح لكل سهم
0
العائد الربحي
0
P/E
10
حجم السوق
841,215,610
أصول ذات صلة
A
ALGN
-3.810
(-1.64%)
228.270 USD
A
ATRC
-0.460
(-2.14%)
21.050 USD
C
CNMD
-3.750
(-5.42%)
65.390 USD
ISRG
6.98
(1.57%)
451.27 USD
N
NUVA
-0.720
(-1.77%)
39.980 USD
O
OFIX
-0.320
(-1.99%)
15.770 USD
S
SMPL
0.100
(0.29%)
34.020 USD
S
SNN
1.975
(6.86%)
30.770 USD
S
STAA
-1.380
(-3.34%)
39.940 USD
الأخبار المقالات

العنوان: MiMedx Group

القطاع: Healthcare
الصناعة: Biotechnology
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.